Skip to main
PCRX
PCRX logo

Pacira Pharmaceuticals (PCRX) Stock Forecast & Price Target

Pacira Pharmaceuticals (PCRX) Analyst Ratings

Based on 28 analyst ratings
Buy
Strong Buy 32%
Buy 21%
Hold 43%
Sell 4%
Strong Sell 0%

Bulls say

Pacira BioSciences, Inc. is projected to achieve substantial revenue growth, with forecasts for 2025 increased by 4-10%, leading to anticipated total revenue of $775 million, a 10.6% year-over-year increase. The company's gross margins are expected to improve to the 76%-78% range, indicating enhanced operational efficiency. Additionally, significant investments in research and development, projected to rise by 21%-42% year-over-year, underscore the commitment to advancing its product pipeline, particularly focusing on PCRX-201, which may further bolster future revenue growth.

Bears say

Pacira BioSciences faces a challenging outlook due to anticipated revenue growth rates that are perceived as low, with guidance suggesting 3-9% year-over-year growth, which may not meet market expectations. The company's projected adjusted selling, general, and administrative expenses are high, estimated between $290-320 million, potentially exceeding operational efficiencies and straining profitability. Furthermore, concerns surrounding Exparel's market exclusivity, coupled with a conservative revenue forecast and a discount rate of 10% in the discounted cash flow analysis, contribute to a bearish sentiment on the stock's long-term performance.

Pacira Pharmaceuticals (PCRX) has been analyzed by 28 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 21% recommend Buy, 43% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pacira Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pacira Pharmaceuticals (PCRX) Forecast

Analysts have given Pacira Pharmaceuticals (PCRX) a Buy based on their latest research and market trends.

According to 28 analysts, Pacira Pharmaceuticals (PCRX) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pacira Pharmaceuticals (PCRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.